- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07900607
The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.
About 8 healthy men will join the study, so that at least 6 people complete it. Each participant will drink a single dose of OD-001 as a liquid. This will be done on an empty stomach, so each participant will be asked not to eat for a period of time beforehand.
The medicine contains a small amount of a radioactive "tracer" (carbon-14). The tracer lets researchers follow the medicine and its breakdown products through your body. The amount of radioactivity is small and carefully limited. After the dose, researchers will collect samples such as blood, urine and stool. These will show how much of the medicine is recovered and what it turns into in the body.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Kelly Bourdon
- Telefonnummer: 857-393-6160
- E-post: clinicaltrials@odysseytx.com
Studiesteder
-
-
-
Ruddington, Storbritannia
- Rekruttering
- Quotient Sciences
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: +44 (0)115 974 9000
- E-post: clinicaltrials@odysseytx.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Aged 30 to 65 years inclusive at the time of signing informed consent
- Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of the procedure Healthy male participants according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs, single 12-lead ECGs, and laboratory safety tests without any clinically significant abnormalities as measured at screening. ECGs and vital signs to be re-checked at pre-dose.
- Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
- Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).
Exclusion Criteria:
- Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
- History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, UC, CD, Irritable Bowel Syndrome or malabsorption syndrome that may impair bioavailability, and neurological or psychiatric disorder
- Participants who are unable to take oral medication.
- Acute diarrhea, constipation or vomiting in the 7 days before the predicted Day 1. If screening occurs >7 days before Day 1his criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: [14C]OD-001
oral solution |
[14C]OD-001 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Mass balance recovery of total radioactivity in all excreta: CumAe
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Rate of elimination of [14C]OD-001 in excreta by Ae
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by %Ae
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by Cum%Ae by interval
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of treatment-emergent adverse events
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Percentage of [14C] total radioactivity OD-001 metabolites in excreta
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Tmax of OD-001 in blood, total radioactivity in blood and plasma
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Cmax of OD-001 in blood, total radioactivity in blood and plasma
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
AUC0-last of OD-001 in blood, total radioactivity in blood and plasma
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
T1/2 of OD-001 in blood, total radioactivity in blood and plasma
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal clinical laboratory test results
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal electrocardiograms (ECGs)
Tidsramme: Day 1 to Day 8
|
Day 1 to Day 8
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Sharan Sidhu, MBChB, BAO, MRCS, MFPM, Quotient Sciences
- Studieleder: Anthony Opipari, Odyssey Therapeutics, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- OD-001-100
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .